

Refractory ascites

Hepatology Day

Beirut, May 28, 2011

Alexandre Pariente, Pau, France

Thanks to Christophe Bureau, Toulouse

Plan

- Definition
- Incidence and Prognosis
- General Measures
- Specific measures
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
- Recommendations
- 2 news about β blockers and clonidine

Definition

- “Ascites that cannot be mobilized or the early recurrence of which cannot be prevented by medical therapy”
- **1 Diuretic-resistant ascites** : lack of response to dietary sodium and intensive diuretic treatment (400 mg of spironolactone and 160 mg of furosemide)
- **2 Diuretic-intractable ascites** : diuretics can not be used because of the development of complications (encephalopathy, renal impairment, hyponatremia, hyperkalemia or hypokalemia...) that preclude the use of an effective diuretic dosage

Definition

Treatment duration : at least 1 week


Lack of response : mean weight loss < 0.8 kg over 4 days and urinary sodium output less than the sodium intake

Early ascites recurrence : recurrence of grade 2 or 3 ascites within 4 weeks after initial mobilization

Diuretic-induced complications :


- **encephalopathy** in the absence of any other precipitating factors
- ↑ **serum creatinine** by >100 % to a value >2 mg/dl (177 uM)
- ↓ **serum sodium** by >10 mmol to a serum sodium <125 mmol/l
- **serum potassium** < 3 mmol/l or > 6 mmol/l

RA is rare and severe



...and in France

- 93 % intractable-ascites
- 7 % resistant-ascites
- 1 yr survival : 52 %
- Survival predictive factors
 - Age, HCC, diabetes, persistence of alcohol



No. at risk 75 53 38 36 22 16

Fig. 2. Probability of survival in patients with cirrhosis and refractory ascites.

Don't forget...

- To eliminate other causes of « refractory » ascites (cardiac ascites, pancreatitis, tuberculosis, malignant ascites and hypothyroidism...)
- To evaluate the heart
- To look for PVT and HCC
- To measure natriuresis

So, Refractory Ascites is

- diuretic-intractable ascites in most cases
- a severe complication occurring in 10 % of patients
- resulting in poor quality of life, high risk of spontaneous bacterial peritonitis and hepatorenal syndrome
- a sign of end stage liver disease associated with poor survival

Plan


- Definition
- Incidence and Prognosis
- **General Measures**
- Specific measures
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
- Recommendations
- 2 news about β blockers and clonidine

General measures


- Ascitic fluid should be examined to rule out **SBP**
 - The **cause** of cirrhosis must be treated (alcohol withdrawal, antiviral therapy etc...)
 - A **precipitating factor** must be looked for (PVT,HCC)
 - Patients should be maintained on a **low sodium diet** (90 mmol/d)
 - **Diuretics** can be discontinued (sodium urinary excretion <30 mmol/d)
- SBP and HRS** must be prevented (nephrotoxic antibiotics, NSAID's, hypotensive agents, iodine contrast media)

Plan

- Definition
- Incidence and Prognosis
- General Measures
- **Specific measures**
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
- Recommendations
- 2 news about β blockers and clonidine




Liver Transplantation



MELD underestimates early mortality in patients with Refractory Ascites


- 507 cirrhotics on TList
- 61/296 (21%) death < J180
– Mean MELD 21



Plan



- Definition
- Incidence and Prognosis
- General Measures
- **Specific measures**
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
 - Vasoconstrictors
 - Beta-blockers

LVP and post-paracentesis induced circulatory dysfunction



A : Patients with circulatory dysfunction
B : Patients without circulatory dysfunction

LVP and post-paracentesis induced circulatory dysfunction




A : Patients with circulatory dysfunction
 B : Patients without circulatory dysfunction

Diuretics


- Inefficacy in $> 90\%$ of patients
 - Stop definitely if complications
 - Pursue if natriuresis is > 30 mM/d

Plan


- Definition
- Incidence and Prognosis
- General Measures
- **Specific measures**
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - **Transjugular Intra Hepatic Shunt (TIPS)**
- Recommendations
- 2 news about β blockers and clonidine




TIPS effects



TIPS effects ²




TIPS effects ³





Paracentesis

or TIPS ?




TIPS vs PA

5 trials, 4 metaanalyses

N=330

42 % vs 80 %

Recurrence of ascites




TIPS vs PA

5 trials, 4 metaanalyses

N=330

54 % vs 36 %




TIPS vs PA


5 trials, 4 metaanalyses

N=330

46 % vs 50 %




Meta-analysis according to individual data



Cumulative probability of transplant-free survival according to treatment allocation


Salerno F et al. Gastroenterology 2007;133:825

Meta-analysis according to individual data




Cumulative probability of transplant-free survival according to treatment allocation

Meta-analysis according to individual data




Cumulative probability of transplant-free survival according to treatment allocation

1-year survival in 105 patients treated by TIPS for RA



Prospective validation



AUROC

- Bilirubine 0.668


- Plaquettes 0.823

< 50 μmol/l bilirubine : sensibilité 95 % - spécificité of 31 %

Plaquettes > 75 000 : sensibilité 95 %, spécificité 32 %

External validation (Barcelona)

Figure 4: Actuarial rates of survival in the 40 patients with cirrhosis and refractory ascites treated with TIPS according to serum bilirubin concentration and platelet count



AUROC

- Bilirubine 0.803


- Plaquettes 0.750

< 50 μmol/l bilirubine : sensibilité 89 % - spécificité of 46 %

Plaquettes > 75 000 : sensibilité 77 %, spécificité 68 %



Covered stents for TIPS



Covered stents for TIPS





Fig. 2. Probability of remaining free of encephalopathy after the transjugular intrahepatic portosystemic shunts (TIPS)

Plan

- Definition
- Incidence and Prognosis
- General Measures
- **Specific measures**
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
- **Recommendations**
- 2 news about β blockers and clonidine

Recommendations

- Repeated LVP with albumin infusion (8 g/L of ascites removed) is the first line of treatment for refractory ascites (A1). Diuretics should be discontinued in patients with RA who do not excrete > 30 mM of sodium under treatment.

Recommendations 2

- TIPS is effective in the management of RA but is associated with a high risk of encephalopathy and studies have not been shown to convincingly improve survival compared with LVP (A1).
- TIPS could be considered in patients with very frequent requirement of LVP, or in those in whom paracentesis is ineffective (e.g. due to the presence of loculated ascites (B1)

Recommendations 3

- Resolution of ascites after TIPS is slow and most patients require continued administration of diuretics and salt restriction (B1)
- TIPS cannot be recommended in patients with severe liver failure (serum bilirubin > 5 mg/dL, INR > 2 or Child-Pugh score > 11 , current encephalopathy > 1 or chronic hepatic encephalopathy), concomitant active infection, progressive renal failure, or severe cardiopulmonary disease (B1)

Plan

- Definition
- Incidence and Prognosis
- General Measures
- **Specific measures**
 - Liver Transplantation
 - Large Volume Paracentesis (LVP)
 - Transjugular Intra Hepatic Shunt (TIPS)
- Recommendations
- **2 news about β blockers and clonidine**

Deleterious effect of propranolol in patients with RA ?

- Observational single-center study
- 151 patients with refractory ascites
- LVP with albumin
- 77 took beta blockers for the prevention of GI bleeding
- Median follow-up 8 months
- 1-year survival 41 %
 - Propranolol 19% (IC 95%: 8-29%)
 - Non Propranolol 64% (IC 95%: 52-76%)

QuickTime™ et un décompresseur sont requis pour visionner cette image.

Deleterious effect of propranolol in patients with RA ?

- Independent factors of mortality

QuickTime™ et un
décompresseur
sont requis pour visionner cette image.

Propranolol and Post-Paracentesis Circulatory Dysfunction

- 10 patients with RA treated with propranolol
- Self control cross over study
- Before, D0 and D7
- Then eradication of VO by banding, and new identical study without propranolol
- PPCD
 - 80% on propranolol
 - 20% off propranolol

On

QuickTime™ et un décompresseur sont requis pour visionner cette image.

Off

QuickTime™ et un décompresseur sont requis pour visionner cette image.

Clonidine in Refractory Ascites

- RCT, 270 patients with RA
- β blockers 35 vs 37%
- Spironolactone and furosemide on individual basis
- Clonidine 0,075 mg x 2 /d/3 months vs nothing
- Response : 20% decrease in body weight and 20% increase in U_{NaV} at 1 and 3 months

Clonidine in Refractory Ascites

- ↓Aldosterone, PRA, Norepi
- ↑ UNaV, GFR
- Response :
 - 1 month 55%
 - 3 months 60%
- Responders:
 - ↓Paracentesis (9 vs 13/3m)

QuickTime™ et un décompresseur sont requis pour visionner cette image.



Thank you for your attention